Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...

Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to appear soon after birth. To date, there haven’t been many reliable ...

It acts as a sort of molecular fumigator to battle phages and plasmids. CRISPR-Cas9 has long been likened to a kind of genetic scissors, thanks to its ability to snip out any desired section of DNA ...

CRISPR has incurred nearly $500 million in losses over the past four quarters. It's burning through cash as the result of its its gene-editing therapy's slow rollout. But its development partner, ...

Infection with the pathogenic yeast fungus Candida auris (C. auris) can wreak havoc on the health of hospital patients and ...

CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from ...

CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, is an advanced technology developed in 2012 that can be used to edit genes. It can be used to find specific DNA sequences inside ...

You’re reading Book Currents, a weekly column in which notable figures share what they’re reading. Sign up for the Goings On newsletter to receive their selections, and other cultural recommendations, ...